Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we were honored to receive the Arvind Hundal Scale-up Award for “showing inspirational growth.” We are proud, humbled, and truly grateful for this recognition. Following in the…
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is n industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title Bacterial vaginosis: Understanding the impact of antibiotic and antibiotic-free treatments on the vaginal microbiome and risk of recurrence. Please meet her in this short interview.……
Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant with the company since April 2023 and is now a permanent employee. In her new role, she will focus on the CE marking of pHyph and initiate the commercial-scale production of…
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners and new investors exceeded the board’s mandate, and an extraordinary general meeting resolved a directed issue to include the oversubscription of SEK 13 million. In total, Gedea…
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola holds a degree in business adminsitration from Lund University and has over 25 years of experience in the life science industry. His previous roles include CFO positions at Pharmiva…
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment…
The Swedish femtech company Gedea Biotech completes important clinical trial on vaginal fungal infection
The Swedish femtech company Gedea Biotech, which is developing an antibiotic-free treatment for vaginal infections, today announced that all patients in the EpHect study have been included and commenced treatment with pHyph. Results from the study are expected in the second quarter of this year.
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins
Gedea Biotech raises 1.5 MEUR (16.5 MSEK) in oversubscribed rights issue as registration CL3-2 trial begins Lund, Sweden, November 15, 2023: Gedea Biotech today announced that it has raised 1.5 MEUR (16,5 MSEK) to initiate and accelerate clinical trial activities supporting pHyph™ applicable for…
Gedea Biotech receives approval to initiate the pivotal NEFERTITI-2 clinical study documenting the performance of pHyph for treatment of bacterial vaginosis
This pivotal study aims to confirm the safety and efficacy of pHyph in treating and preventing BV recurrence Patient recruitment will now be initiated and 5 Swedish clinics are planned to attend Previous studies in BV have demonstrated pHyph to have a BV cure rate in line with antibiotics on the…